From: Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
Endpoints | Evolocumab dosages | Mean Difference, % (95 % CI) | Test for overall effect | Number of studies | Number of individuals | Heterogeneity | Publication bias | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
Z | P value | Evolocumab | Placebo | I 2 | P value | P_Begg | P_Egger | ||||
TC | 420 mg Q4W | −36.66 (−38.93, −34.39) | 31.60 | 0.000 | 6 | 539 | 825 | 38.0 % | 0.153 | 1.000 | 0.980 |
140 mg Q2W | −40.48 (−45.33, −35.62) | 16.35 | 0.000 | 4 | 456 | 730 | 85.3 % | 0.000 | 0.734 | 0.552 | |
HDL-C | 420 mg Q4W | 7.58 (5.69, 9.46) | 7.89 | 0.000 | 9 | 688 | 1121 | 23.3 % | 0.236 | 1.000 | 0.843 |
140 mg Q2W | 6.90 (5.37, 8.43) | 8.84 | 0.000 | 6 | 586 | 993 | 0.0 % | 0.551 | 0.133 | 0.030 | |
Non-HDL-C | 420 mg Q4W | −52.11 (−55.07, −49.14) | 34.42 | 0.000 | 8 | 672 | 1088 | 57.9 % | 0.020 | 0.618 | 0.499 |
140 mg Q2W | −56.07 (−61.67, −50.47) | 19.62 | 0.000 | 6 | 586 | 993 | 89.0 % | 0.000 | 0.452 | 0.616 | |
TC/HDL-C | 420 mg Q4W | −41.26 (−45.65, −36.87) | 18.43 | 0.000 | 6 | 317 | 374 | 64.7 % | 0.015 | 0.566 | 0.302 |
140 mg Q2W | −44.85 (−49.11, −40.59) | 20.64 | 0.000 | 4 | 229 | 285 | 63.6 % | 0.041 | 0.089 | 0.126 | |
VLDL-C | 420 mg Q4W | −22.75 (−27.46, −18.04) | 9.47 | 0.000 | 6 | 567 | 925 | 6.6 % | 0.374 | 0.452 | 0.335 |
140 mg Q2W | −24.83 (−38.29, −11.38) | 3.62 | 0.000 | 4 | 480 | 831 | 82.3 % | 0.001 | 0.734 | 0.462 | |
ApoB | 420 mg Q4W | −45.14 (−49.16, −41.12) | 22.00 | 0.000 | 9 | 688 | 1121 | 78.8 % | 0.000 | 0.076 | 0.027 |
140 mg Q2W | −52.69 (−57.40, −47.98) | 21.91 | 0.000 | 6 | 586 | 993 | 85.6 % | 0.000 | 0.707 | 0.450 | |
ApoA1 | 420 mg Q4W | 5.17 (2.60, 7.73) | 3.95 | 0.000 | 6 | 317 | 374 | 40.6 % | 0.135 | 0.566 | 0.517 |
140 mg Q2W | 6.26 (1.71, 10.82) | 2.69 | 0.007 | 4 | 230 | 285 | 74.5 % | 0.008 | 0.308 | 0.129 | |
ApoB/ApoA1 | 420 mg Q4W | −48.06 (−52.70, −43.43) | 20.32 | 0.000 | 7 | 395 | 527 | 72.4 % | 0.001 | 0.649 | 0.351 |
140 mg Q2W | −53.68 (−57.77, −49.59) | 25.74 | 0.000 | 5 | 305 | 438 | 65.8 % | 0.020 | 0.806 | 0.500 | |
TG | 420 mg Q4W | −15.70 (−20.35, −11.05) | 6.62 | 0.000 | 9 | 688 | 1121 | 42.5 % | 0.084 | 0.118 | 0.030 |
140 mg Q2W | −17.35 (−23.50, −11.20) | 5.53 | 0.000 | 6 | 586 | 993 | 59.8 % | 0.029 | 1.000 | 0.039 | |
Lp(a) | 420 mg Q4W | −25.40 (−29.09, −21.70) | 13.47 | 0.000 | 9 | 688 | 1121 | 47.1 % | 0.057 | 1.000 | 0.626 |
140 mg Q2W | −32.39 (−38.92, −25.87) | 9.73 | 0.000 | 6 | 586 | 993 | 79.3 % | 0.000 | 1.000 | 0.819 | |
PCSK9 | 420 mg Q4W | −44.04 (−53.90, −34.17) | 8.75 | 0.000 | 6 | 540 | 908 | 85.2 % | 0.000 | 0.452 | 0.473 |
140 mg Q2W | −60.92 (−83.94, −37.89) | 5.18 | 0.000 | 2 | 132 | 188 | 92.9 % | 0.000 | 1.000 | NA |